Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T for Post-Transplant B-ALL
NCT04336501Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Dec 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of IM19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Overall Response Rate at 6 months. Status: unknown.
02
Drugs
IM19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04336501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04336501.